Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

International Journal of Oncology

Volumn 44, Issue 3, 2014, Pages 662-668

  Higashihara, Yoshie ^a   Kato, Junko ^a   Nagahara, Akihito ^a   Izumi, Kentaro ^a   Konishi, Masae ^a   Kodani, Tomohiro ^a   Serizawa, Nobuko ^a   Osada, Taro ^a   Watanabe, Sumio ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric cancer; Phase I clinical trial; URLC10; Vaccination therapy; VEGFR1

Indexed keywords

CANCER VACCINE; CISPLATIN; DOCETAXEL; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HLA A ANTIGEN; IRINOTECAN; METHOTREXATE; PACLITAXEL; PEPTIDE VACCINE; UNCLASSIFIED DRUG; URLC10 A24 177 EPITOPE PEPTIDE; VASCULOTROPIN RECEPTOR 1; VEGFR1 A12 9 1084 EPITOPE PEPTIDE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG SAFETY; EDEMA; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; GENOTYPE; HLA SYSTEM; HUMAN; HYPERURICEMIA; HYPOALBUMINEMIA; HYPONATREMIA; IMMUNE RESPONSE; MALE; MIDDLE AGED; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RASH; STOMACH CANCER; UNIVERSITY HOSPITAL; VOMITING;

ADULT; AGED; CANCER VACCINES; EPITOPES; FEMALE; HLA-A ANTIGENS; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; VACCINES, SUBUNIT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84896738852     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2242     Document Type: Article

References (24)

1. Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, et al: Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 10: 1266-1279, 2010.
2. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordic F, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized control trial. Lancet 376: 687-697, 2010.
3. Cheever MA and Higano CS: PROVENGE (Sipuleusel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17: 3520-3526, 2011.
4. Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, et al: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell esophageal cancer. Cancer Sci 100: 1502-1509, 2009.
5. Miyazawa M, Ohsawa R, Tsunoda T, Hirono S, Kawai M, Tani M, Nakamura Y, et al: Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci 101: 433-439, 2010.
6. Kato J, Nagahara A, Kotani T, Higashihara Y, Matsumura Y, Osada T, Yoshizawa T, et al: Phase I clinical trial of peptide vaccination with KIF20 and VEGFR1 epitope peptides in patients with advanced pancreatic cancer. Pancreatic Dis Ther 2: 102, 2012.
7. Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, Okazaki N, et al: Heteroclitic serological response in esophageal and prostate cancer patient after NY-ESO-1 protein vaccination. Int J Cancer 130: 584-592, 2012.
8. Watanabe T, Suda T, Tsunoda T, Uchida N, Ura K, Kato T, Hasegawa S, et al: Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinoma. Cancer Sci 96: 498-506, 2005. (Pubitemid 41387302)
9. Komori H, Nakahara T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, et al: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12: 2689-2697, 2006.
10. Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, et al: Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancer. Clin Cancer Res 14: 6487-6495, 2008.
11. Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Kataguri T, Fukukawa Y, et al: Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 10: 8630-8640, 2004. (Pubitemid 40053431)
12. Ishizaki H, Tsynoda T, Wada S, Yamauchi M, Shibuya M and Tahara H: Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res 12: 5841-5849, 2006. (Pubitemid 44629617)
13. Mizukami Y, Kono K, Daigo Y, Takano A, Tsunoda T, Kawaguchi Y, Nakamura Y, et al: Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 99: 1448-1454, 2008. (Pubitemid 351761737)
14. Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, et al: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 10: 141, 2012.
15. Suda T, Tsunoda T, Daigo Y, Nakamura Y and Tahara H: Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancer as novel targets for immunotherapy. Cancer Sci 98: 1803-1808, 2007. (Pubitemid 47489730)
16. Fujiwara Y, Kishi K, Yano M, Mototsugu M, Ishikawa O, Okada K, Masuzawa T, et al: Peptide vaccination for gastric cancer. J Gastrointest Res 20: 120-127, 2012.
17. Van der Brunggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde, Kunth A, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991. (Pubitemid 21917508)
18. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, et al: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23: 8950-8958, 2005. (Pubitemid 46211480)
19. Hattori T, Mine T, Komatsu N, Yamada A, Itoh K, Shiozaki H and Okumo K: Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 58: 1843-1852, 2009.
20. Shimokawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y and Furukawa Y: Identification of TOMMO34, which shows elevated expression in the majority of human colon cancer, as a novel drug target. Int J Oncol 29: 381-386, 2006.
21. Masuzawa T, Fujiwara Y, Okada K, Nakamura A, Takiguchi S, Nakajima K, Miyata H, et al: Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol 41: 1297-1304, 2012.
22. Sato Y, Shomura H, Maeda Y, Mine T, Ueno Y, Akasaka Y, Kondo M, et al: Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94: 802-808, 2003. (Pubitemid 37258779)
23. Miyagi Y, Imai N, Sasatomi T, Yamada A, Mine T, Katagiri K, Nakagawa M, et al: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin Cancer Res 7: 3950-3962, 2001. (Pubitemid 34044613)
24. Koizumi W, Nakahara H, Hara T, Takigane A, Akiya T, Takagi M, Miyashita K, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.